(Q37692210)

22 August 2017

1 reference

title

Off-label use of rituximab in systemic lupus erythematosus: a systematic review (English)

1 reference

systemic lupus erythematosus

22 August 2017

0 references

1 reference

1 reference

Eleanor Murray

1

1 reference

PubMed ID

20155295

22 August 2017

Martin Perry

series ordinal

2

1 reference

22 August 2017

13 February 2010

1 reference

22 August 2017

Clinical Rheumatology

1 reference

22 August 2017

29

1 reference

22 August 2017

7

1 reference

22 August 2017

707-716

1 reference

Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden

22 August 2017

1 reference

12 December 2020

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.

1 reference

12 December 2020

Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production

1 reference

12 December 2020

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

1 reference

12 December 2020

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

1 reference

12 December 2020

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

1 reference

12 December 2020

Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?

1 reference

12 December 2020

Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.

1 reference

12 December 2020

Prevention of relapses in systemic lupus erythematosus

1 reference

12 December 2020

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

12 December 2020

B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity.

1 reference

12 December 2020

Six refractory lupus patients treated with rituximab: a case series

1 reference

12 December 2020

Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?

1 reference

12 December 2020

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

1 reference

12 December 2020

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

12 December 2020

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

1 reference

12 December 2020

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

1 reference

12 December 2020

The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus

1 reference

12 December 2020

B cell non-Hodgkin's lymphoma: rituximab safety experience

1 reference

12 December 2020

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

1 reference

12 December 2020

Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome

1 reference

12 December 2020

Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study

1 reference

12 December 2020

How does B cell depletion therapy work, and how can it be improved?

1 reference

12 December 2020

EULAR points to consider for conducting clinical trials in systemic lupus erythematosus

1 reference

12 December 2020

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

1 reference

12 December 2020

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

1 reference

12 December 2020

Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice

1 reference

12 December 2020

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

1 reference

12 December 2020

A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines

1 reference

12 December 2020

The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

1 reference

12 December 2020

Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy

1 reference

12 December 2020

A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus

1 reference

12 December 2020

Effects of rituximab on resistant SLE disease including lung involvement.

1 reference

12 December 2020

High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus

1 reference

12 December 2020

Rituximab for treatment of patients with systemic autoimmune diseases

1 reference

12 December 2020

B cell abnormalities in systemic lupus erythematosus

1 reference

12 December 2020

Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy

1 reference

12 December 2020

Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents

1 reference

12 December 2020

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis

1 reference

12 December 2020

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

1 reference

12 December 2020

Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology

1 reference

12 December 2020

Predictors of survival in systemic lupus erythematosus

1 reference

12 December 2020

B cell immunobiology in disease: evolving concepts from the clinic

1 reference

12 December 2020

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

1 reference

12 December 2020

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab

1 reference

12 December 2020

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

1 reference

12 December 2020

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

1 reference

12 December 2020

10.1007/S10067-010-1387-5

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20155295